In the Margins

Valeant names hedge fund partner to board

October 26, 2015

By Forbes

Valeant Pharmaceuticals has named Mason Morfit, a partner at activist hedge fund ValueAct Capital, to its board of directors. Morfit previously served on the embattled specialty drugmaker's board from 2007 to 2014; ValueAct is one of Valeant's largest shareholders. Read the original story from Forbes

 

 

Most Read

10 Things
10 Things...Boards will face in 2023

As mutual fund board members look forward to 2023, which is just around the corner, they are faced with a number of challenges and tasks unique ...